Clinical Outcomes of Gonadotropin-Releasing Hormone Agonist Therapy in Children with Central Precocious Puberty
https://doi.org/10.15605/jafes.041.S1
- Author:
Siti Zakiyyah Bakhtiar
1
;
Jia Nyuk Chong
1
;
Hooi Peng Cheng
2
Author Information
1. Department of Pharmacy, Sarawak General Hospital
2. Department of Paediatrics, Sarawak General Hospital
- Publication Type:Journal Article
- MeSH:
Child;
Puberty, Precocious;
Gonadotropin-Releasing Hormone
- From:
Journal of the ASEAN Federation of Endocrine Societies
2026;41(S1):138-139
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Central precocious puberty (CPP) is the premature
activation of the hypothalamic-pituitary-gonadal axis, often
compromising adult height and psychosocial well-being.
Timely treatment with gonadotropin-releasing hormone
agonists (GnRHa) such as triptorelin is critical to halt
pubertal progression and preserve growth potential. This
study evaluated the clinical outcomes of triptorelin therapy
in CPP at Sarawak General Hospital (SGH).
Methodology:A retrospective cross-sectional study was conducted among
patients with CPP treated with triptorelin at the Paediatric
Endocrine Clinic, SGH, including those currently receiving therapy and those who had discontinued treatment.
Demographic and clinical data were extracted from medical
records and analyzed using SPSS version 25. Descriptive
statistics summarized patient characteristics, while t-tests
and non-parametric equivalents assessed treatment
outcomes (p <0.05 significant).
Results:Eleven patients were included (mean age 6.88 ± 2.21 years;
90.9% female). Two patients (18.2%) were obese at initial
diagnosis, and the mean baseline body mass index was
17.64 ± 2.25 kg/m². Most cases were idiopathic (54.5%),
while pituitary microadenoma was identified in 36.4%.
At diagnosis, the bone age was advanced by a mean of
3.51 ± 1.39 years. Six patients discontinued therapy: four
after completion and two at parental request. Among
completers, mean treatment duration was 3.21 ± 2.42 years,
ending at a mean age of 10.13 ± 0.95 years. Final height did
not differ significantly from mid-parental height (p = 0.225).
Triptorelin significantly improved final height standard
deviation score (SDS) (p = 0.005) and reduced the bone age/
chronological age ratio (p = 0.049), though predicted adult
height gains were not statistically significant (p = 0.321).
No adverse effects were reported.
Conclusion:GnRHa therapy slowed pubertal progression and preserved
growth potential in children with CPP, with favorable
safety outcomes. Larger prospective studies are warranted
to validate long-term benefits and identify predictors of
optimal response.
- Full text:2026081013224806168EP_P008.pdf
